
Michael Liang
SlowingNamed in filings at LightX CapitalOn the current fund
- Board seats filed
- 13

Named in filings at LightX CapitalOn the current fund
all filings on record
last 24 months
from a verified or cited source
| Infinant Health | Biotech & pharma | May 2026 | Longitude Capital |
| NEOCHORD | Medical devices | April 2021 | Baird Venture Partners, BioStar Ventures, Treo Ventures, U.S Venture Partners |
| JumpCode Genomics | Biotech & pharma | December 2020 | Arboretum Ventures |
| Greenlight Biosciences | Biotech & pharma | June 2020 | None on file |
| Oncology Analytics | Digital health | April 2020 | Oak HC/FT, Sandbox Clinical Ventures |
| APERVITA | Digital health | October 2019 | SNAK Venture Partners |
| Alto Neuroscience | Biotech & pharma | September 2019 | None on file |
| AIC Innovations Group | Manufacturing & industrials | July 2017 | None on file |
| GENOMEDX BIOSCIENCES | Biotech & pharma | February 2016 | None on file |
| Zurex Pharma | Biotech & pharma | June 2014 | None on file |
| Integrated Diagnostics | Digital health | April 2014 | None on file |
| Insightra Medical | Medical devices | April 2014 | None on file |
| Amphora Medical | Medical devices | May 2013 | Baird Venture Partners |
The company and date are what the SEC filing shows, not a statement of investment thesis. A partner can sit on a board for reasons that say nothing about what their firm funds today. The category is not a filing value: it is Lev’s own classification of each company, shown only when we found a specific, checkable source for it; otherwise it reads “Not yet classified.” “Also on the board from” names another tracked firm with a partner on the same board, both with a clean identity match. It is not a claim either firm led or co-led the round, and “None on file” means no other tracked firm’s partner shares this specific board seat, not that no one else invested. Sorted newest first by default; click a column to change it. Something wrong? Tell us.
Categories of companies where filings name Michael Liang on the board, based on 13 filed seats with a verified or cited source.